A Study of the Safety of Mibavademab in Pediatric and Adult Participants Switching From Metreleptin to Mibavademab for the Treatment of Generalized Lipodystrophy (GLD) | MicrobiomeTrials
A Study of the Safety of Mibavademab in Pediatric and Adult Participants Switching From Metreleptin to Mibavademab for the Treatment of Generalized Lipodystrophy (GLD)
CompletedPHASE3INTERVENTIONAL
Trial Details
Start: 2024-12-16Est. Completion: 2026-07-09
Enrollment target: 9 participants
Locations
National Institutes of Health, Bethesda, Maryland, United States
University of Michigan, Ann Arbor, Michigan, United States
Other microbiome trials you might be interested in